Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.67 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 3/20 | 0.35 |
| ▸ | ACE | P12821 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15333593 | 1.00 | PTGS1 (0.67) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL15348170 | 0.99 | PTGS1 (0.65) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL209654 | 0.91 | PTGS1 (0.70) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL931787 | 0.91 | PTGS1 (0.70) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL31067315 | 0.89 | PTGS1 (0.56) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL29421937 | 0.87 | PTGS1 (0.50) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL30123057 | 0.87 | PTGS1 (0.50) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL30903459 | 0.87 | GLO1 (0.50) | PTGS1GSTK1DPP4DPP8DPP9 | |
| Glutathione SCHEMBL6465767 | 0.87 | PTGS1 (0.90) | PTGS1GSTK1GLO1BLMKMT2A | |
| Glutathione SCHEMBL27657060 | 0.87 | PTGS1 (0.90) | PTGS1GSTK1GLO1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118897023-B | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2025-03-25 | — | — | CN | claimed |
| EP-2721051-A1 | A METHOD FOR THE PRODUCTION OF HYDROLYZED ALLERGENS | Biotech Tools S.A. (BE) | 2014-04-23 | — | — | EP | claimed |
| EP-2664614-A1 | PALLADIUM-COPPER CATALYSTS FOR THE HOMOGENEOUS SELECTIVE OXIDATION OF THIOL GROUPS | "Ivy Pharm" Limited Liability Company (RU) | 2013-11-20 | — | — | EP | claimed |
| US-20130289108-A1 | Palladium-Copper Catalysts for the Homogeneous Selective Oxidation of Thiol Groups | "IVY PHARM" LIMITED LIABILITY COMPANY (RU) | 2013-10-31 | — | — | US | claimed |
| CN-103380108-A | Palladium-copper catalyst for homogeneous selective oxidation of thiol groups | IVY PHARM LTD LIABILITY COMPANY | 2013-10-30 | — | — | CN | claimed |
| WO-2012172037-A1 | A METHOD FOR THE PRODUCTION OF HYDROLYZED ALLERGENS | BIOTECH TOOLS S.A. (BE) | 2012-12-20 | — | — | WO | claimed |
| EP-2398500-A2 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB Holding B.V. (NL) | 2011-12-28 | — | — | EP | claimed |
| WO-2010095940-A2 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2010-08-26 | — | — | WO | claimed |
| EP-2032145-A2 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | The Board of Regents of The University of Texas System (US) | 2009-03-11 | — | — | EP | claimed |
| WO-2008002678-A2 | STRUCTURAL-BASED INHIBITORS OF THE GLUTATHIONE BINDING SITE IN ALDOSE REDUCTASE, METHODS OF SCREENING THEREFOR AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-01-03 | — | — | WO | claimed |
| EP-1641488-A1 | EPITOPE COMPOSITION FOR SUBLINGUAL, BUCCAL OR ENTERIC ADMINISTRATION PREPARED BY HYDROLYSIS OF ANTIGENIC STRUCTURES WITH CHYMOTRYPSIN | BioTech Tools S.A. (BE) | 2006-04-05 | — | — | EP | claimed |
| WO-2004112833-A1 | EPITOPE COMPOSITION FOR SUBLINGUAL, BUCCAL OR ENTERIC ADMINISTRATION PREPARED BY HYDROLYSIS OF ANTIGENIC STRUCTURES WITH CHYMOTRYPSIN | BIOTECH TOOLS SA (BE) | 2004-12-29 | — | — | WO | claimed |
| US-6239111-B1 | DRUG FOR TREATING BRAIN DISEASES, ENABLES PREVENTION OR TREATMENT OF DEMENTIA AND SIMILAR DISEASES CAUSED BY DEGENERATION OR SLOUGHING OF NEURONS, AN ALLY SULFIDE, SULFOXIDE OR SULFONE | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | claimed |
| EP-0604433-A4 | COMPOSITION AND METHOD FOR DISEASE TREATMENT. | LIFE SCIENCES TECH INC (US) | 1994-10-12 | — | — | EP | claimed |
| EP-0604433-A1 | COMPOSITION AND METHOD FOR DISEASE TREATMENT | LIFE SCIENCES' TECHNOLOGIES, INC. (US) | 1994-07-06 | — | — | EP | claimed |
| WO-1992021368-A1 | COMPOSITION AND METHOD FOR DISEASE TREATMENT | LIFE SCIENCES' TECHNOLOGIES, INC. (US) | 1992-12-10 | — | — | WO | claimed |
| JP-10273438-A | — | — | None | — | — | JP | disclosed |
| US-12544417-B2 | Oral film and stick jelly for improving absorption in the oral mucosa, antioxidant activity, anti-inflammatory activity, and liver function of humans and companion animals | ESTHER FORMULA CO., LTD. (KR) | 2026-02-10 | — | — | US | disclosed |
| EP-0081122-B1 | CARRIER TRIPEPTIDES WITH ANTIFUNGAL ACTIVITY | Helopharm W. Petrik GmbH & Co.KG. (DE) | 1985-10-02 | — | — | EP | disclosed |
| EP-0081122-A1 | Carrier tripeptides with antifungal activity | Helopharm W. Petrik GmbH & Co.KG. (DE) | 1983-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544417-B2 | Oral film and stick jelly for improving absorption in the oral mucosa, antioxidant activity, anti-inflammatory activity, and liver function of humans and companion animals | SELL, ICAM1, MB | PTGS1 557/4885GSTK1 25/4885DPP4 3193/4885 |
| US-20130289108-A1 | Palladium-Copper Catalysts for the Homogeneous Selective Oxidation of Thiol Groups | SOD1, SOD3, GSTM2 | PTGS1 828/4885GSTK1 41/4885DPP4 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.